Skip to main content

Clinical Trials Using Darolutamide

Review the clinical trials studying darolutamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 319 locations
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Status: Active
Location: 15 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Status: Active
Location: 7 locations
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Status: Active
Location: 8 locations
MRI-Guided LEAD Stereotactic Radiotherapy with or without Ultra-Short Term Androgen Suppression Therapy for the Treatment of Prostate Cancer, the Miami UAdapt Trial
Status: Active
Location: 4 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Status: Active
Location: 5 locations
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Status: Active
Location: 3 locations
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Status: Active
Location: 2 locations
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Alternating High Dose Testosterone and Darolutamide for the Treatment of Metastatic Prostate Cancer Patients who have not Received Treatment, SPIDERMAN Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Darolutamide Alone or in Combination with Standard Therapy before Surgery for the Treatment of Stage II-IIIA, Androgen Receptor Positive, Triple-Negative Breast Carcinoma
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer
Status: Active
Location: 2 locations
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York